Injective INJ
Current Price
$5.79 +3.10%
$0.4300 Daily Range (7.43%)
$5.62$6.05
$74.55M Daily Volume
857 BTC
Vol/MktCap: 12.83%
Market Performance
0.12% Relative BTC Volume
The total volume of Injective is $74.55M over the past 24 hours, compared to $60.98B total Bitcoin volume.
Hourly Moving Average
8 SMA $5.89 -1.68%
13 SMA $5.91 -2.04%
21 SMA $5.87 -1.41%
55 SMA $5.73 +1.02%
144 SMA $5.65 +2.55%
Price Performance
-1.23% 1 Hour Change
$5.79 from $5.86
-14.18% 7 Day Change
-$0.8213 from $6.61
-27.00% 14 Day Change
-$1.56 from $7.35
-33.56% 30 Day Change
-$1.94 from $7.73
All Time High
March 14, 2024
$52.62 -88.97%
-$46.82 vs. now
24H Change
18.40M USD +3.27%
212 BTC
Volume and Supply
Total Supply: 100.00M INJ 
100.00M INJ Available100.00% circulating A lower circulating supply may increase over time, reducing scarcity and potentially causing a drop in price. A higher circulating supply is less susceptible to dilution, offering the potential for a more stable price long-term.
Relative Supply Ratio
5.01 x BTC Supply5:1 supply ratio
RSR reflects potential differences in tokenomics, such as inflation rates, utility, or burn mechanisms, which can impact long-term value and scarcity.
Relative Trade Volume
12.78M INJ
traded over past 24 hours
12.78% of circulating supply
A higher trade volume relative to market cap indicates strong market activity and liquidity, while a lower ratio may suggest reduced interest, lower liquidity, or potential price stagnation.
Conversion Tool
Injective AI Market Analysis
Injective (INJ) is currently trading at $5.80, exhibiting a 24-hour price change of 2.40%. The daily trading range has been relatively narrow, with a high of $6.05 and a low of $5.60, indicating moderate volatility.
The trading volume stands at approximately 77.3 million, which equates to a volume/market cap ratio of 13.30%. This suggests a healthy level of trading activity compared to its market capitalization, indicating interest among traders despite recent price declines.
Moving averages indicate a mixed sentiment: the 8-day SMA shows a decline of 2.03% at $5.92, while the longer-term 55 and 144-day SMAs are both showing positive trends, with increases of 2.16% and 2.19%, respectively. The short-term RSI of 59 indicates that the asset is approaching overbought conditions, while the 7-day RSI of 45 suggests bearish momentum in the medium term.
From a fundamental perspective, Injective has experienced significant price corrections over the past month, with a 30-day price drop of approximately 33.50%. The all-time high of $52.62, reached in March 2024, highlights the volatility and potential for recovery, but the current price levels reflect substantial retracement from these highs.
Given the recent price action and technical indicators, the outlook remains cautiously optimistic. While short-term fluctuations suggest a potential rebound, the overall trend points to a need for consolidation before any significant upward movement can be sustained.
Based on this analysis, a Hold rating is recommended for Injective (INJ). This is due to the mixed signals from moving averages and RSI indicators, combined with significant historical price corrections, suggesting that investors may want to wait for clearer bullish signals before committing additional capital.
The trading volume stands at approximately 77.3 million, which equates to a volume/market cap ratio of 13.30%. This suggests a healthy level of trading activity compared to its market capitalization, indicating interest among traders despite recent price declines.
Moving averages indicate a mixed sentiment: the 8-day SMA shows a decline of 2.03% at $5.92, while the longer-term 55 and 144-day SMAs are both showing positive trends, with increases of 2.16% and 2.19%, respectively. The short-term RSI of 59 indicates that the asset is approaching overbought conditions, while the 7-day RSI of 45 suggests bearish momentum in the medium term.
From a fundamental perspective, Injective has experienced significant price corrections over the past month, with a 30-day price drop of approximately 33.50%. The all-time high of $52.62, reached in March 2024, highlights the volatility and potential for recovery, but the current price levels reflect substantial retracement from these highs.
Given the recent price action and technical indicators, the outlook remains cautiously optimistic. While short-term fluctuations suggest a potential rebound, the overall trend points to a need for consolidation before any significant upward movement can be sustained.
Based on this analysis, a Hold rating is recommended for Injective (INJ). This is due to the mixed signals from moving averages and RSI indicators, combined with significant historical price corrections, suggesting that investors may want to wait for clearer bullish signals before committing additional capital.
Updated 202 minutes ago.
Injective Relative Price at Market Cap of:
Injective TradingView Chart
In The News

Grayscale files for Zcash ETF to broaden crypto access
Grayscale's ETF filing could enhance institutional adoption of privacy-focused cryptocurrencies, potentially reshaping digital asset investment.

Metaplanet Leverages 30,823 $BTC for $130M Loan. Bitcoin Hyper Rides the Wave Into a $28.5M Presale
Quick Facts: ➡️ Metaplanet’s $130M Bitcoin-backed loan shows corporates increasingly treat $BTC as long-term collateral rather than a trading asset.

Hedera Stabilizes as Bullish Divergence and Rising Momentum Indicate Turnaround
Hedera Hashgraph is showing early signs of a potential trend reversal after analysts identified a bullish divergence on the daily chart.

Texas Allocates $5M into BlackRock’s $BTC ETF as Bitcoin Hyper Raises Over $28.5M
Quick Facts: ➡️ Texas allocating $5M into a BlackRock Bitcoin ETF during a dip shows a growing state-level conviction in Bitcoin’s long-term upside.